PEGylated liposomes

immunological responses

Marwa Mohamed, Amr S. Abu Lila, Taro Shimizu, Eman Alaaeldin, Amal Hussein, Hatem A. Sarhan, J. Szebeni, Tatsuhiro Ishida

Research output: Review article

Abstract

A commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-immunogenic. However, many studies have reported that unexpected immune responses have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid clearance of PEGylated nanocarriers upon repeat administration, called the accelerated blood clearance (ABC) phenomenon. ABC involves the production of antibodies toward nanocarrier components, including PEG, which reduces the safety and effectiveness of encapsulated therapeutic agents. Another immune response is the hypersensitivity or infusion reaction referred to as complement (C) activation-related pseudoallergy (CARPA). Such immunogenicity and adverse reactivities of PEGylated nanocarriers may be of potential concern for the clinical use of PEGylated therapeutics. Accordingly, screening of the immunogenicity and CARPA reactogenicity of nanocarrier-based therapeutics should be a prerequisite before they can proceed into clinical studies. This review presents PEGylated liposomes, immunogenicity of PEG, the ABC phenomenon, C activation and lipid-induced CARPA from a toxicological point of view, and also addresses the factors that influence these adverse interactions with the immune system.

Original languageEnglish
Pages (from-to)710-724
Number of pages15
JournalScience and Technology of Advanced Materials
Volume20
Issue number1
DOIs
Publication statusPublished - dec. 31 2019

Fingerprint

Liposomes
Polyethylene glycols
Chemical activation
Blood
Immune system
Antibodies
Lipids
Screening

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., ... Ishida, T. (2019). PEGylated liposomes: immunological responses. Science and Technology of Advanced Materials, 20(1), 710-724. https://doi.org/10.1080/14686996.2019.1627174

PEGylated liposomes : immunological responses. / Mohamed, Marwa; Abu Lila, Amr S.; Shimizu, Taro; Alaaeldin, Eman; Hussein, Amal; Sarhan, Hatem A.; Szebeni, J.; Ishida, Tatsuhiro.

In: Science and Technology of Advanced Materials, Vol. 20, No. 1, 31.12.2019, p. 710-724.

Research output: Review article

Mohamed, M, Abu Lila, AS, Shimizu, T, Alaaeldin, E, Hussein, A, Sarhan, HA, Szebeni, J & Ishida, T 2019, 'PEGylated liposomes: immunological responses', Science and Technology of Advanced Materials, vol. 20, no. 1, pp. 710-724. https://doi.org/10.1080/14686996.2019.1627174
Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA et al. PEGylated liposomes: immunological responses. Science and Technology of Advanced Materials. 2019 dec. 31;20(1):710-724. https://doi.org/10.1080/14686996.2019.1627174
Mohamed, Marwa ; Abu Lila, Amr S. ; Shimizu, Taro ; Alaaeldin, Eman ; Hussein, Amal ; Sarhan, Hatem A. ; Szebeni, J. ; Ishida, Tatsuhiro. / PEGylated liposomes : immunological responses. In: Science and Technology of Advanced Materials. 2019 ; Vol. 20, No. 1. pp. 710-724.
@article{54db8e56f8cc4d8692e87e5e6efc43ef,
title = "PEGylated liposomes: immunological responses",
abstract = "A commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-immunogenic. However, many studies have reported that unexpected immune responses have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid clearance of PEGylated nanocarriers upon repeat administration, called the accelerated blood clearance (ABC) phenomenon. ABC involves the production of antibodies toward nanocarrier components, including PEG, which reduces the safety and effectiveness of encapsulated therapeutic agents. Another immune response is the hypersensitivity or infusion reaction referred to as complement (C) activation-related pseudoallergy (CARPA). Such immunogenicity and adverse reactivities of PEGylated nanocarriers may be of potential concern for the clinical use of PEGylated therapeutics. Accordingly, screening of the immunogenicity and CARPA reactogenicity of nanocarrier-based therapeutics should be a prerequisite before they can proceed into clinical studies. This review presents PEGylated liposomes, immunogenicity of PEG, the ABC phenomenon, C activation and lipid-induced CARPA from a toxicological point of view, and also addresses the factors that influence these adverse interactions with the immune system.",
keywords = "Accelerated blood clearance (ABC) phenomenon, anti-PEG IgM, complement activation, complement activation-related pseudoallergy (CARPA), hypersensitivity reactions (HSRs), PEGylated liposomes, polyethylene glycol (PEG)",
author = "Marwa Mohamed and {Abu Lila}, {Amr S.} and Taro Shimizu and Eman Alaaeldin and Amal Hussein and Sarhan, {Hatem A.} and J. Szebeni and Tatsuhiro Ishida",
year = "2019",
month = "12",
day = "31",
doi = "10.1080/14686996.2019.1627174",
language = "English",
volume = "20",
pages = "710--724",
journal = "Science and Technology of Advanced Materials",
issn = "1468-6996",
publisher = "IOP Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - PEGylated liposomes

T2 - immunological responses

AU - Mohamed, Marwa

AU - Abu Lila, Amr S.

AU - Shimizu, Taro

AU - Alaaeldin, Eman

AU - Hussein, Amal

AU - Sarhan, Hatem A.

AU - Szebeni, J.

AU - Ishida, Tatsuhiro

PY - 2019/12/31

Y1 - 2019/12/31

N2 - A commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-immunogenic. However, many studies have reported that unexpected immune responses have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid clearance of PEGylated nanocarriers upon repeat administration, called the accelerated blood clearance (ABC) phenomenon. ABC involves the production of antibodies toward nanocarrier components, including PEG, which reduces the safety and effectiveness of encapsulated therapeutic agents. Another immune response is the hypersensitivity or infusion reaction referred to as complement (C) activation-related pseudoallergy (CARPA). Such immunogenicity and adverse reactivities of PEGylated nanocarriers may be of potential concern for the clinical use of PEGylated therapeutics. Accordingly, screening of the immunogenicity and CARPA reactogenicity of nanocarrier-based therapeutics should be a prerequisite before they can proceed into clinical studies. This review presents PEGylated liposomes, immunogenicity of PEG, the ABC phenomenon, C activation and lipid-induced CARPA from a toxicological point of view, and also addresses the factors that influence these adverse interactions with the immune system.

AB - A commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-immunogenic. However, many studies have reported that unexpected immune responses have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid clearance of PEGylated nanocarriers upon repeat administration, called the accelerated blood clearance (ABC) phenomenon. ABC involves the production of antibodies toward nanocarrier components, including PEG, which reduces the safety and effectiveness of encapsulated therapeutic agents. Another immune response is the hypersensitivity or infusion reaction referred to as complement (C) activation-related pseudoallergy (CARPA). Such immunogenicity and adverse reactivities of PEGylated nanocarriers may be of potential concern for the clinical use of PEGylated therapeutics. Accordingly, screening of the immunogenicity and CARPA reactogenicity of nanocarrier-based therapeutics should be a prerequisite before they can proceed into clinical studies. This review presents PEGylated liposomes, immunogenicity of PEG, the ABC phenomenon, C activation and lipid-induced CARPA from a toxicological point of view, and also addresses the factors that influence these adverse interactions with the immune system.

KW - Accelerated blood clearance (ABC) phenomenon

KW - anti-PEG IgM

KW - complement activation

KW - complement activation-related pseudoallergy (CARPA)

KW - hypersensitivity reactions (HSRs)

KW - PEGylated liposomes

KW - polyethylene glycol (PEG)

UR - http://www.scopus.com/inward/record.url?scp=85068089055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068089055&partnerID=8YFLogxK

U2 - 10.1080/14686996.2019.1627174

DO - 10.1080/14686996.2019.1627174

M3 - Review article

VL - 20

SP - 710

EP - 724

JO - Science and Technology of Advanced Materials

JF - Science and Technology of Advanced Materials

SN - 1468-6996

IS - 1

ER -